{"entity":{"id":"paper-zeta-vandetanib-mtc-wells-jco-2012","kind":"paper","name":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer","aka":[],"tldr":"Vandetanib was the first drug shown to delay progression in medullary thyroid cancer, roughly doubling progression-free survival compared with placebo, and became the first approved therapy for the disease.","summary":"Phase 3 placebo-controlled trial of 331 patients with unresectable locally advanced or metastatic medullary thyroid cancer randomised 2:1 to vandetanib 300 mg daily or placebo.\n\nMedian progression-free survival was predicted at 30.5 versus 19.3 months (hazard ratio 0.46) with response 45 versus 13 percent (placebo responses reflecting slow disease and crossover); QT prolongation, diarrhoea and rash were the main toxicities.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2012","url":"https://doi.org/10.1200/JCO.2011.35.5040"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/22025146/"}],"tags":[],"related":[],"cancers":["medullary-thyroid-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["vandetanib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["zeta"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2012,"doi":"10.1200/JCO.2011.35.5040","pmid":"22025146","authors":"Wells SA, Robinson BG, Gagel RF, et al.","paperType":"rct","findings":["Progression-free survival hazard ratio 0.46; predicted median 30.5 vs 19.3 months.","Objective response 45 percent vs 13 percent."],"whatItMeans":"Vandetanib is an approved option for progressive medullary thyroid cancer, used less since selpercatinib for RET-mutant disease.","caveats":["Enrolled patients with indolent disease, some not progressing; QT monitoring required."],"changedPractice":true,"participants":331},"route":"/key-papers/paper-zeta-vandetanib-mtc-wells-jco-2012/","neighbours":{"cancer":[{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/"}],"drug":[{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/"}],"trial":[{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}